Nanobiotix (NBTX) has released an update.
Nanobiotix, a late-clinical stage biotech firm focused on nanoparticle-based therapies for cancer, has announced the addition of Dr. Margaret A. Liu and Ms. Anat Naschitz to its Supervisory Board. Dr. Liu brings a wealth of experience in vaccines, gene therapy, and cancer immunotherapy, while Ms. Naschitz offers extensive expertise as a life science investor and entrepreneur. Their appointments aim to bolster Nanobiotix’s strategic growth and innovative capabilities in oncology and beyond.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.
